ArticleLaboratory investigation; a journal of technical methods and pathology2017
Microfluidics-assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 assessment in breast cancer.
Article in Laboratory investigation; a journal of technical methods and pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- A multi-depth spiral milli fluidic device for whole mount zebrafish antibody staining.Biomedical microdevices · 2023Article
- Attomolar Sensitivity in Single Biomarker Counting upon Aqueous Two-Phase Surface Enrichment.ACS sensors · 2022Article
- In Situ Flow Cytometer Calibration and Single-Molecule Resolution via Quantum Measurement.Sensors (Basel, Switzerland) · 2022Article
- Microfluidics combined with fluorescenceFrontiers in bioengineering and biotechnology · 2022Article
- Advances in Microfluidics for the Implementation of Liquid Biopsy in Clinical Routine.Advances in experimental medicine and biology · 2022Article
- FISH and chips: a review of microfluidic platforms for FISH analysis.Medical microbiology and immunology · 2020Review
- Microfluidic Device for On-Chip Immunophenotyping and Cytogenetic Analysis of Rare Biological Cells.Cells · 2020Article
- Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.Virchows Archiv : an international journal of pathology · 2019Article
- High-content, cell-by-cell assessment of HER2 overexpression and amplification: a tool for intratumoral heterogeneity detection in breast cancer.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- A microfluidic platform towards automated multiplexed in situ sequencing.Scientific reports · 2019Article
- Combining fluorescence-based image segmentation and automated microfluidics for ultrafast cell-by-cell assessment of biomarkers for HER2-type breast carcinoma.Journal of biomedical optics · 2018Article
- Rapid micro fluorescenceBiomicrofluidics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluorescence in situ hybridization (FISH) is one of the recommended techniques for human epidermal growth factor receptor 2 (HER2) status assessment on cancer tissues. Here we develop microfluidics-assisted FISH (MA-FISH), in which hybridization of the FISH probes with their target DNA strands is obtained by applying square-wave oscillatory flows of diluted probe solutions in a thin microfluidic chamber of 5 μl volume. By optimizing the experimental parameters, MA-FISH decreases the consumption of the expensive probe solution by a factor 5 with respect to the standard technique, and reduces the hybridization time to 4 h, which is four times faster than in the standard protocol. To validate the method, we blindly conducted HER2 MA-FISH on 51 formalin-fixed paraffin-embedded tissue slides of 17 breast cancer samples, and compared the results with standard HER2 FISH testing. HER2 status classification was determined according to published guidelines, based on average number of HER2 copies per cell and average HER2/CEP17 ratio. Excellent agreement was observed between the two methods, supporting the validity of MA-FISH and further promoting its short hybridization time and reduced reagent consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.